There is a strong consensus globally that production of an effective vaccine against SARS-CoV-2 is likely the most effective approach to sustainably controlling the COVID-19 pandemic An unprecedented research effort and global coordination has resulted in a rapid development of vaccine candidates and initiation of trials In this paper, we review vaccine candidate against COVID-19 and also challenges of vaccination have been explored in different region
Background: The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing due to the growing epidemics of obesity. Omentin-1 is an anti-inflammatory adipokine produced preferentially by visceral adipose tissue. The aim of this study was to determine omentin-1 serum levels and its relationship with body mass index, fasting blood sugar and lipid profile. Materials and methods: This case-control study was performed on 70 patients with non-alcoholic fatty liver disease and 70 participants as controls. Plasma levels of omentin 1 were measured by ELISA kit and other variables were determined by standard methods. Data were analyzed using SPSS version 20 software. Results: Patients with non-alcoholic fatty liver presented significantly higher omentin levels compared to the controls (p<0.05). NAFLD patients had significantly higher levels of body mass index (BMI) and triglycerides, compared to healthy group (p-value<0.05). An inverse correlation was observed between omentin1with BMI, triglyceride, and LDL-C (p<0.05), but were positively associated with HDL-C levels (p<0.05). We did find correlation between omentin-1 with FBS in patients with non-alcoholic fatty liver (p<0.05). Conclusion: The findings showed that omentin-1 serum levels were significantly different in patients with NAFLD when compared to controls. Omentin levels are correlated with BMI, LDL-C, and HDL-C.
